Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - Net
Ratios

Tandem Diabetes Care (TNDM) R&D In Process (2022 - 2025)

Tandem Diabetes Care (TNDM) has disclosed R&D In Process for 3 consecutive years, with $17000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, R&D In Process changed N/A year-over-year to $17000.0, compared with a TTM value of $75.2 million through Dec 2025, changed N/A, and an annual FY2025 reading of $75.2 million, changed N/A over the prior year.
  • R&D In Process was $17000.0 for Q3 2025 at Tandem Diabetes Care, down from $75.2 million in the prior quarter.
  • Across five years, R&D In Process topped out at $78.8 million in Q1 2023 and bottomed at $17000.0 in Q3 2025.
  • Average R&D In Process over 3 years is $37.0 million, with a median of $31.0 million recorded in 2022.